Clinical trials demonstrate sustained weight loss, appetite suppression, and cardiometabolic improvements for 2+ years at constant doses, without the need for ongoing escalation
Typical symptoms include fatigue, weakness, pale skin, shortness of breath, and neurological manifestations such as numbness, tingling in the extremities, memory problems, and difficulty walking
Importantly, these medications carry a boxed warning for risk of thyroid C-cell tumors and are contraindicated in patients with personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN2)
Cagrilintide Dosage Chart This cagrilintide dosage chart summarizes the standalone 16-week titration ladder from 0.25 mg weekly to the 2.4 mg weekly research-target dose
These symptoms are a direct byproduct of the drug slowing down gastrointestinal transit times